Research programme: nicotine inhalation - Addicere Therapeutics

Drug Profile

Research programme: nicotine inhalation - Addicere Therapeutics

Alternative Names: Staccato-nicotine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Addicere Therapeutics
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (Inhalation, Aerosol)
  • 31 Dec 2013 Staccato® nicotine is no longer licensed to Cypress Bioscience worldwide (Alexza Pharmaceuticals Form 10-K for 2013)
  • 12 Apr 2012 Preclinical trials in Smoking withdrawal in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top